DNA topoisomerase II in therapy-related acute promyelocytic leukemia

New England Journal of Medicine

Volumn 352, Issue 15, 2005, Pages 1529-1538

  Mistry, Anita R ^a   Felix, Carolyn A ^b,c   Whitmarsh, Ryan J ^b   Mason, Annabel ^a   Reiter, Andreas ^d   Cassinat, Bruno ^e   Parry, Anne ^e   Walz, Christoph ^d   Wiemels, Joseph L ^f   Segal, Mark R ^f   Adès, Lionel ^g   Blair, Ian A ^c   Osheroff, Neil ^h   Peniket, Andrew J ⁱ   Lafage Pochitaloff, Marina ^j   Cross, Nicholas C P ^k   Chomienne, Christine ^e   Solomon, Ellen ^a   Fénaux, Pierre ^g   Grimwade, David ^a,l,m  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e SAINT LOUIS HOSPITAL   (France)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITÉ PARIS 13   (France)

^h VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^j INSERM   (France)

^k WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

^l UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^m GUY S HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOUBLE STRANDED DNA; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GYRASE INHIBITOR; MITOXANTRONE; ONCOPROTEIN; TAMOXIFEN; VINCRISTINE; ANTINEOPLASTIC AGENT; DNA;

ARTICLE; BREAST CANCER; CHIMERA; CHROMOSOME TRANSLOCATION; DNA REPAIR; DNA STRAND BREAKAGE; HUMAN; IN VITRO STUDY; INTRON; LARYNX CANCER; LEUKEMOGENESIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SEQUENCE ANALYSIS; CHEMICALLY INDUCED DISORDER; DNA DAMAGE; DNA SEQUENCE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE TRANSLOCATION; GENETICS; METABOLISM; SECOND CANCER;

ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA REPAIR; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DOXORUBICIN; ETOPOSIDE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MITOXANTRONE; NEOPLASMS, SECOND PRIMARY; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TRANSLOCATION, GENETIC;

EID: 20144388623     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa042715     Document Type: Article

References (39)

1. Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001;14:497-529.
2. Rowley JD. Chromosome translocations: dangerous liaisons revisited. Nat Rev Cancer 2001;1:245-50.
3. Mistry AR, Pedersen EW, Solomon E, Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev 2003;17:71-97.
4. Piazza F, Gurrieri C, Pandolfi PP. The theory of APL. Oncogene 2001;20:7216-22.
5. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002;99:1909-12.
6. Felix CA. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol 2001;36:525-35.
7. Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer 2002;33:331-45.
8. Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 2000;64:221-53.
9. Negrini M, Felix CA, Martin C, et al. Potential topoisomerase II DNA-binding sites at the breakpoints of a t(9;ll) chromosome translocation in acute myeloid leukemia. Cancer Res 1993;53:4489-92.
10. Ahuja HG, Felix CA, Apian PD. Potential role for DNA topoisomerase II poisons in the generation of t(11;20)(p15;q11) translocations. Genes Chromosomes Cancer 2000;29:96-105.
11. Domer PH, Head DR, Renganathan N, Raimondi SC, Yang E, Atlas M. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). Leukemia 1995;9:1305-12.
12. Apian PD, Chervinsky DS, Stanulla M, Burhans WC. Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors. Blood 1996;87:2649-58.
13. Strissel PL, Strick R, Rowley JD, Zeleznik-Le NJ. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region. Blood 1998;92:3793-803.
14. Zhang Y, Strissel P, Strick R, et al. Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia. Proc Natl Acad Sci U S A 2002;99:3070-5.
15. Dong S, Geng JP, Tong JH, et al. Breakpoint clusters of the PML gene in acute promyelocytic leukemia: primary structure of the reciprocal products of the PML-RARA gene in a patient with t(15;17). Genes Chromosomes Cancer 1993;6:133-9.
16. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998;92:2322-33.
17. Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003;21:2123-37.
18. Pulsoni A, Pagano L, Lo Coco F, et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood 2002;100:1972-6.
19. Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC, Pedersen-Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002;33:395-400.
20. Carli PM, Sgro C, Parchin-Geneste N, et al. Increase therapy-related leukemia secondary to breast cancer. Leukemia 2000;14:1014-7.
21. Reiter A, Saussele S, Grimwade D, et al. Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. Genes Chromosomes Cancer 2003;36:175-88.
22. Grimwade D, Howe K, Langabeer S, et al. Establishing the presence of the t(15;17) in suspected acute promyelocyric leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. Br J Haematol 1996;94:557-73.
23. Lovett BD, Strumberg D, Blair IA, et al. Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry 2001:40:1159-70.
24. Whitmarsh RJ, Saginario C, Zhuo Y, et al. Reciprocal DNA topoisomerase II cleavage events at 5′-TATTA-3′ sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing. Oncogene 2003;22:8448-59.
25. Segal MR, Wiemels JL. Clustering of translocation breakpoints. J Am Stat Assoc 2002;97:66-76.
26. Glaz J, Naus JI, Wallenstein S. Scan statistics. New York: Springer-Verlag, 2001.
27. Loader CR. Large deviation approximations to the distribution of scan statistics. Adv Appl Probab 1991;23:751-71.
28. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003;3:639-49.
29. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003;102:43-52.
30. Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994;83:2780-6.
31. Lovett BD, Lo Nigro L, Rappaport EF, et al. Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. Proc Natl Acad Sci U S A 2001;98:9802-7.
32. Betti CJ, Villalobos MJ, Diaz MO, Vaughan AT. Apoptotic triggers initiate translocations within the MLL gene involving the norihomologous end joining repair system. Cancer Res 2001;61:4550-5.
33. Idem. Apoptotic stimuli initiate MLL-AF9 translocations that are transcribed in cells capable of division. Cancer Res 2003;63:1377-81.
34. Eguchi-Ishimae M, Eguchi M, Ishii E, et al. Breakage and fusion of the TEL (ETV6) gene in immature B lymphocytes induced by apoptogenic signals. Blood 2001;97:737-43.
35. Stanulla M, Wang J, Chervinsky DS, Thandla S, Apian PD. DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis. Mol Cell Biol 1997;17:4070-9.
36. Kudo K, Yoshida H, Kiyoi H, Numata S, Horibe K, Naoe T. Etoposide-related acute promyelocytic leukemia. Leukemia 1998;12:1171-5.
37. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999;17:569-77.
38. Megonigal MD, Cheung NK, Rappaport EF, et al. Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc Natl Acad Sci U S A 2000;97:2814-9.
39. Bloomfield CD, Archer KJ, Mrozek K, et al. 11q23 Balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002;33:362-78.